Skip to main content
Premium Trial:

Request an Annual Quote

Genometrix Withdraws Initial Public Offering; Plans to Seek Private Financing

NEW YORK, Feb 26 – Genometrix on Monday withdrew its application for an initial public offering, citing poor market conditions.

“The markets are so volatile, we decided not to proceed with it [the offering] at this time,” said Bobbie Ireland, senior manager of marketing communications at Genometrix of The Woodlands, Texas.

Ireland said the company, which filed for the IPO with the US Securities and Exchange Commission last March, has recently started working with banks in an effort to secure private financing.

According to the company’s original S-1 filing, Genometrix had $6.5 million cash and cash equivalents at the end of December 1999. Ireland said that Genometrix had not raised any money since the filing.

She declined to say what if any measures the company of 100 employees had taken to pump up its cash reserves or to discuss revenues.

“We won’t discuss the finances,” she said.

Genometrix, a developer of custom-design and prefabricated microarrays as well as software tools used to analyze gene expression data, originally planned to offer seven million shares at $10 - $12 a share. 

Several companies have delayed IPOs over the past several months due to concerns over market conditions. Third Wave Technologies, which recently jumped into the market waters, succeeded in selling its shares, but has since watched the share price sink.  

Motorola holds a 16.4 percent stake in Genometrix, according to the most recent SEC filing.



The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Sanction Violation Charges

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.